Global Hyperphosphatemia Drugs Market 2015-2019

PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Product profiles
PART 05: Introduction
Key market highlights
PART 06: Disease Overview
Understanding the disease
Etiology
Effects of hyperphosphatemia
Causes
Signs and symptoms
Diagnosis
Management
Epidemiology
PART 07: Key developments in hyperphosphatemia therapy
PART 08: Guidelines for use of phosphate binders
CKD stages 2-4
CKD stage 5
PART 09: Pipeline analysis
Information on Pipeline Candidates
PART 10: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 11: Hyperphosphatemia management market dynamics
PART 12: Market segmentation by dosage form
Solid
Liquid
PART 13: Market segmentation by formulation
Aluminum-based phosphate binders
Calcium-based phosphate binders
Aluminum-free, calcium-free phosphate binder
Magnesium-based phosphate binders
Iron-based phosphate binders
PART 14: Geographical segmentation
Global hyperphosphatemia drugs market by Geography 2014-2019
Hyperphosphatemia drugs market in the Americas
Hyperphosphatemia drugs market in EMEA
Hyperphosphatemia drugs market in APAC
PART 15: Key leading countries
Hyperphosphatemia drugs market in the US
Hyperphosphatemia drugs market in Japan
PART 16: Market drivers
PART 17: Impact of drivers
PART 18: Market challenges
PART 19: Impact of drivers and challenges
PART 20: Market trends
PART 21: Vendor landscape
Competitive Scenario
Market Share Analysis 2014
Brand differentiation
Other prominent vendors
PART 22: Key vendor analysis
Fresenius Medical Care
Keryx Biopharmaceuticals, Inc.
Sanofi SA
Shire
Vifor Pharma
PART 23: Appendix
List of abbreviation